You traded AVXL very well. I suppose I shouldn't have responded to your CTIX comment here on the AVXL board. I think that you are underestimating the value of the CTIX pipeline. It certainly is undervalued now as compared to other small biotechs with lesser pipelines. Market cap is a convenient way to compare how a company is being valued relative to the valuations of similar companies. A company with 5 clinical trials in progress with promising results so far ought to have a market cap of more than 154 million. NNVC, with zero clinical trials and none in sight, has a market cap that is 2/3 of CTIX's. Crazy.